Find Sodium Iodide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

4 RELATED EXCIPIENT COMPANIES

8EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 7681-82-5, Ioduril, Sodium monoiodide, Soiodin, Iodure de sodium, Sodium iodide (nai)
Molecular Formula
INa
Molecular Weight
149.8942  g/mol
InChI Key
FVAUCKIRQBBSSJ-UHFFFAOYSA-M
FDA UNII
F5WR8N145C

Sodium Iodide
A compound forming white, odorless deliquescent crystals and used as iodine supplement, expectorant or in its radioactive (I-131) form as an diagnostic aid, particularly for thyroid function tests.
1 2D Structure

Sodium Iodide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
sodium;iodide
2.1.2 InChI
InChI=1S/HI.Na/h1H;/q;+1/p-1
2.1.3 InChI Key
FVAUCKIRQBBSSJ-UHFFFAOYSA-M
2.1.4 Canonical SMILES
[Na+].[I-]
2.2 Other Identifiers
2.2.1 UNII
F5WR8N145C
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 7681-82-5

2. Ioduril

3. Sodium Monoiodide

4. Soiodin

5. Iodure De Sodium

6. Sodium Iodide (nai)

7. Sodiumiodide

8. Jodid Sodny

9. Sodium;iodide

10. Mfcd00003532

11. Nsc-77388

12. Iodide (as Sodium Iodide)

13. Fdy-5301

14. F5wr8n145c

15. Chembl1644695

16. Chebi:33167

17. Natriumjodid

18. Natrii Iodidum

19. Sodium Iodide, Ultra Dry

20. Jodid Sodny [czech]

21. Caswell No. 777

22. Natriumjodid [german]

23. Hsdb 750

24. Einecs 231-679-3

25. Nsc 77388

26. Epa Pesticide Chemical Code 075702

27. Sodium Iodide [usp:jan]

28. Unii-f5wr8n145c

29. Sodium-iodide

30. Iodeto De Sodio

31. Ioduro Di Sodio

32. Yoduro De Sodio

33. Sodium Iodide-

34. Sodium Iodide,99%

35. Sodium Iodide Solution

36. Sodium Iodide, Anhydrous

37. Sodium Iodide, Acs Grade

38. Wln: Na I

39. Ec 231-679-3

40. Sodium Iodide [ii]

41. Sodium Iodide [mi]

42. Sodium Iodine-131(1-)

43. Dsstox_cid_21125

44. Dsstox_rid_79629

45. Sodium Iodide [jan]

46. Dsstox_gsid_41125

47. Sodium Iodide [hsdb]

48. Sodium Iodide [inci]

49. Sodium Iodide (jp17/usp)

50. Sodium Iodide [vandf]

51. Sodium Iodide [mart.]

52. Sodium Iodide [who-dd]

53. Dtxsid2041125

54. Sodium Iodide, Trace Metals Grade

55. Bcp22179

56. Nsc77388

57. Tox21_301379

58. Sodium Iodide [ep Monograph]

59. Sodium Iodide [usp Monograph]

60. Akos015950612

61. Akos016015354

62. Db11119

63. Ncgc00255631-01

64. Cas-7681-82-5

65. Iodide (as Sodium Iodide) [vandf]

66. Cs-0013799

67. Ft-0645131

68. S0564

69. D04874

70. Q390305

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 149.8942 g/mol
Molecular Formula INa
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count1
Rotatable Bond Count0
Exact Mass149.89424 g/mol
Monoisotopic Mass149.89424 g/mol
Topological Polar Surface Area0 Ų
Heavy Atom Count2
Formal Charge0
Complexity2
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameSodium iodide i 123
PubMed HealthSodium Iodide I 123 (By mouth)
Drug ClassesDiagnostic Agent
Active IngredientSodium iodide i-123
Dosage FormCapsule
RouteOral
Strength100uci; 200uci
Market StatusPrescription
CompanyCardinal Hlth 414; Mallinckrodt

2 of 2  
Drug NameSodium iodide i 123
PubMed HealthSodium Iodide I 123 (By mouth)
Drug ClassesDiagnostic Agent
Active IngredientSodium iodide i-123
Dosage FormCapsule
RouteOral
Strength100uci; 200uci
Market StatusPrescription
CompanyCardinal Hlth 414; Mallinckrodt

4.2 Therapeutic Uses

...CAN BE USED INTERCHANGEABLY WITH POTASSIUM IODIDE, AS A THERAPEUTIC AGENT, EXCEPT WHERE SODIUM ION IS CONTRAINDICATED.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 802


VET: HAS BEEN USED FOR RINGWORM, HYPERPLASTIC FIBROUS LESIONS, PARAPLEGIA FROM PACHYMENINGITIS OF DOGS.

The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 1116


VET: ...IT MAY BE USEFUL IV FOR OTHER MYCOSES, CHRONIC JOINT SWELLINGS, LARYNGITIS, BRONCHITIS, & PLEURITIS IN MANY SPECIES; LUNGWORM INFECTIONS IN CATS; TO IMMOBILIZE THALLIUM IN THE BODY; BY CATHETER INTO THE BLADDER AS AN X-RAY CONTRAST MEDIA...

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 541


DOSE--ORAL, 300 MG TO 2 G DAILY; USUAL, 300 MG 2-4 TIMES A DAY; IV INFUSION, 1-3 G DAILY; USUAL, 1 G.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 802


For more Therapeutic Uses (Complete) data for SODIUM IODIDE (15 total), please visit the HSDB record page.


4.3 Drug Warning

VET: ...MONITOR IODISM. AVOID UNNECESSARY USE IN ADVANCED PREGNANCY...IT MAY PRODUCE GOITER IN NEWBORN. .../AVOID/ USE OF MILK FROM TREATED ANIMALS FOR AT LEAST 72 HR & 6 MILKINGS AFTER SUCH TREATMENT. MAY POTENTIATE BARBITURATE ANESTHESIA IN RATS.

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 541


IODIDES MAY PPT THYROTOXICOSIS WHEN GIVEN TO PT WITH NODULAR GOITERS, OR IN EUTHYROID PT WITH AUTONOMOUS THYROID FUNCTION...DURING REMISSION OF HYPERTHYROIDISM FOLLOWING A COURSE OF THIONAMIDES... IN PT WITH CHRONIC THYROIDITIS, PREVIOUS RADIOIODINE THERAPY OR THYROIDECTOMY, IODIDES MAY INDUCE HYPOTHYROIDISM. /IODIDES/

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 918


CONTRAINDICATIONS (VET): HYPERTHYROIDISM & PREGNANCY. WARNING: ANIMALS VARY IN SUSCEPTIBILITY TO IODIDES. ADMIN WITH CAUTION UNTIL TOLERANCE IS DETERMINED. DISCONTINUE TREATMENT IMMEDIATELY IF SYMPTOMS OF IODISM APPEAR... /SODIUM IODIDE 20%/

Aronson, C.E. (ed.). Veterinary Pharmaceuticals & Biologicals, 1980-1981. Media, Pa.: Harwal Publishing Co., 1980., p. 16/30


POTENTIAL ADVERSE EFFECTS ON FETUS: Goiters, fetal encephalopathy. POTENTIAL SIDE EFFECTS ON BREAST-FED INFANT: May cause skin rash and thyroid suppression in infant. FDA Category:D (D = There is no evidence of human fetal risk but the potential benefits from use in pregnant women may be acceptable despite the potential risks (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective.) /Iodides/ /from table II/

Stockton, D.L. and A.S. Paller. J Am Acad Dermatol 23 (1):87-103 (1990)


4.4 Minimum/Potential Fatal Human Dose

3(?). 3= MODERATELY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 0.5-5 G/KG, BETWEEN 1 OUNCE & 1 PINT (OR 1 LB) FOR 70 KG PERSON (150 LB). /IODIDE SALTS/

Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-78


4.5 Drug Indication

Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).


5 Pharmacology and Biochemistry
5.1 Pharmacology

When intravenously administered for total parental nutrition, sodium iodide prevents the depletion of endogenous stores of iodine and subsequent deficiency symptoms.


5.2 Absorption, Distribution and Excretion

Absorption

Iodide salts are readily absorbed in the gastrointestinal tract.


Route of Elimination

Iodides are expected to be renal excreted.


Volume of Distribution

Iodides are distributed widely throughout extracellular fluid of thyroid gland.


5.3 Mechanism of Action

RESPONSE TO IODIDE IN HYPERTHYROIDISM: /IN THYROID GLAND/...VASCULARITY IS REDUCED, GLAND BECOMES MUCH FIRMER & EVEN HARD TO THE TOUCH, CELLS BECOME SMALLER, COLLOID REACCUMULATES IN FOLLICLES, & QUANTITY OF BOUND IODINE INCREASES. /IODIDES/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1412


HIGH CONCN OF IODIDE APPEAR TO INFLUENCE ALL IMPORTANT ASPECTS OF IODINE METABOLISM BY THE THYROID GLAND. CAPACITY OF IODIDE TO LIMIT ITS OWN TRANSPORT... ACUTE INHIBITION OF SYNTHESIS OF IODOTYROSINE & IODOTHYRONINE BY IODIDE IS ALSO WELL KNOWN (THE WOLFF-CHAIKOFF EFFECT)... /IODIDES/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413


THIS INHIBITION /WOLFF-CHAIKOFF EFFECT/ IS OBSERVED ONLY ABOVE CRITICAL CONCN OF IODIDE, & THE INTRACELLULAR...CONCN OF ANION APPEARS TO BE MAJOR DETERMINANT. WITH TIME THERE IS "ESCAPE" FOR THIS INHIBITION...ASSOCIATED WITH AN ADAPTIVE DECR IN IODIDE TRANSPORT & LOWERED INTRACELLULAR IODIDE CONCN. /IODIDES/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413


THE MOST IMPORTANT CLINICAL EFFECT OF HIGH IODIDE CONCN IS AN INHIBITION OF THE RELEASE OF THYROID HORMONE. THIS ACTION IS RAPID & EFFICACIOUS IN SEVERE THYROTOXICOSIS. THE EFFECT IS EXERTED DIRECTLY ON THE THYROID GLAND, & IT CAN BE DEMONSTRATED IN EUTHYROID SUBJECT & EXPTL ANIMALS AS WELL AS IN HYPERTHYROID PT. /IODIDES/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413


IODIDE ANTAGONIZES THE ABILITY OF BOTH THYROTROPIN & CYCLIC AMP TO STIMULATE ENDOCYTOSIS OF COLLOID, PROTEOLYSIS, & HORMONE SECRETION. /REPORTEDLY/... IODIDE ATTENUATES THE EFFECT OF TSH ON CYCLIC AMP IN VIVO & IN ISOLATED TISSUES. /IODIDES/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Thickeners and Stabilizers

read-more
read-more

Parenteral

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty